Nanobody · Off-the-Shelf Lead Licensing
100+ validated targets delivered, including multi-pass transmembrane and other hard-to-drug classes
Integrated CRO services for antibody therapeutics and in vitro diagnostics — covering antigen preparation, animal immunization, antibody discovery, antibody production and functional evaluation.
Four routes — recombinant protein, nanodisc, VLP and mRNA — fit different needs; recombinant protein SDS-PAGE purity ≥85%, peptide purity ≥95%.
VHH & VNAR routes in parallel; typical project: positive rate ≥30%, EC50 ≤10 nM, with ELISA screening data for ≥20 positive clones
Humanisation & affinity maturation. Rational design + cell validation
Multiple antibody molecule types from 8 species; SEC-HPLC purity ≥85%, with a standard sequence-to-purification timeline of 5-7 weeks
In vitro and in vivo efficacy evaluation, BLI affinity analysis, flow cytometry testing, and multidimensional developability characterisation; complete project delivery with raw experimental data and a full quality control report
Five expression systems — E. coli, mammalian, baculovirus–insect, yeast and cell-free — are selected flexibly for each target, including membrane and toxic proteins; cell-free expression can finish in as little as 5 days.
An integrated service from target screening and molecular engineering through multidimensional developability assessment, evaluating activity, stability, pharmacokinetics and manufacturability to help clients obtain preclinical candidates (PCCs) that meet development standards.
Protein · cell line · antibody per target 200+ targets in stock, data included
For a wide range of challenging targets, SanjingBio's integrated nanobody discovery platform helps innovative drug teams efficiently obtain multidimensionally validated, developable antibody candidates with full intellectual property ownership assigned to the client.
Hard-target expertise
Proven project experience and positive-rate guarantees on membrane proteins, multi-pass transmembrane and other demanding targets.
Function-first screening
ELISA, FACS, BLI, internalisation and cell-function assays assess affinity, specificity and activity together, so developable molecules are identified earlier.
Confidentiality & ownership
Project information, data and the engagement itself stay strictly confidential; every antibody and dataset delivered belongs solely to you, with FTO and novelty search services also available.
Co-development · EFS
Moving beyond traditional molecule licensing, our full CRO technical services offset R&D expenses in exchange for minority equity or single-pipeline revenue rights, sharing R&D investment and pipeline returns with clients
of Team Experience
Monthly Protein Expression Projects
Validated Drug Targets
Target Proteins In Stock
SanjingBio is a CRO focused on nanobody (VHH) discovery and early-stage antibody development, providing innovative drug teams, IVD companies, and research institutions with one-stop technical services from target analysis to functional validation.
Our in-house nanobody discovery platform provides a one-stop workflow spanning antigen preparation, alpaca immunisation, VHH library construction, antibody screening and optimisation, expression and purification, and functional validation. We have completed project validation for 100+ targets, including challenging targets such as membrane proteins. Led by PhDs from Zhejiang University, our team helps partners reduce early-stage R&D trial-and-error costs and efficiently obtain candidates with development potential.
Mesothelin, long underestimated, has moved from the lab to the clinical frontier across CAR-T, ADCs and bispecifics. With our cellular EC50 and internalisation data.
May 27, 2026
Both formats drop parts of the native immunoglobulin. We compare structure, solubility, stability, size and production cost, then their therapeutic use.
Jul 15, 2026
Heavy-chain-only antibodies, found in camelids and cartilaginous fish in the 1990s, lose the CH1 domain and pair no light chain — leaving a single variable domain of roughly 15 kDa, nanometre-scale.
Jun 10, 2026
· Head of Raw Materials
IVD company
“The mouse monoclonal passed our raw-material acceptance criteria. As the core antibody in our diagnostic kit it lifted sensitivity 2.5× over the incumbent, with excellent lot-to-lot consistency.”
· Project Lead
University research group
“We needed a WB-capable antibody against one specific region of the target. SanjingBio picked an 18-mer peptide from extracellular loop site A as the immunogen — the rabbit monoclonal came back highly sensitive.”
· R&D Manager
Research team
“Our autoimmune programme needed an antibody that recognised several epitopes at once. Using >90% pure recombinant protein as the immunogen, both affinity and specificity cleared validation.”
· Head of Cell Platform
Drug developer
“The positive population in the human-target stable cell pool read more than two logs above the negative control, and several high-expressing cynomolgus monoclonal lines were isolated as well.”
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
